Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-08
2010-11-09
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S272000, C514S239200, C514S232200, C514S234200, C514S235500, C514S319000, C514S217050, C514S357000, C544S123000, C544S321000, C544S131000, C544S079000, C544S070000, C544S121000, C544S165000, C544S129000, C544S230000, C544S273000, C546S206000, C546S194000, C546S337000, C540S598000
Reexamination Certificate
active
07829560
ABSTRACT:
1,4 disubstituted napthylenes, of formula (I), are disclosed. These compounds may be useful in treating cell-proliferative diseases.
REFERENCES:
patent: 3455924 (1969-07-01), Ladnicer
patent: 4794114 (1988-12-01), Bender et al.
patent: 4892578 (1990-01-01), Chang et al.
patent: 5317019 (1994-05-01), Bender et al.
patent: 5777097 (1998-07-01), Lee et al.
patent: 5783664 (1998-07-01), Lee et al.
patent: 5869043 (1999-02-01), McDonnell et al.
patent: 5871934 (1999-02-01), Lee et al.
patent: 5955366 (1999-09-01), Lee et al.
patent: 5994412 (1999-11-01), Lee et al.
patent: 6033873 (2000-03-01), McDonnell et al.
patent: 6090626 (2000-07-01), Monia et al.
patent: 6162613 (2000-12-01), Su et al.
patent: 6187799 (2001-02-01), Wood et al.
patent: 6302838 (2001-10-01), O'Reilly et al.
patent: 6344476 (2002-02-01), Ranges et al.
patent: 6376214 (2002-04-01), Kumar
patent: 6387641 (2002-05-01), Bellon et al.
patent: 6410518 (2002-06-01), Monia
patent: 6437147 (2002-08-01), Andersen et al.
patent: 6683100 (2004-01-01), van Hoogevest
patent: 6689883 (2004-02-01), Boyer et al.
patent: 6806258 (2004-10-01), Monia
patent: 2001/0006975 (2001-07-01), Wood et al.
patent: 2002/0042517 (2002-04-01), Uday et al.
patent: 2002/0058659 (2002-05-01), Andersen et al.
patent: 2002/0137774 (2002-09-01), Riedl et al.
patent: 2002/0165394 (2002-11-01), Dumas et al.
patent: 2003/0078432 (2003-04-01), Letavic et al.
patent: 2003/0125359 (2003-07-01), Lyons et al.
patent: 2003/0144278 (2003-07-01), Riedl et al.
patent: 2003/0181442 (2003-09-01), Riedl et al.
patent: 2003/0207872 (2003-11-01), Riedl et al.
patent: 2003/0207914 (2003-11-01), Dumas et al.
patent: 2003/0216396 (2003-11-01), Dumas et al.
patent: 2003/0216446 (2003-11-01), Dumas et al.
patent: 2004/0023961 (2004-02-01), Dumas et al.
patent: 2004/0087626 (2004-05-01), Renhowe et al.
patent: 2004/0122237 (2004-06-01), Amiri et al.
patent: 0 951 467 (2003-04-01), None
patent: 1 114 051 (2003-04-01), None
patent: 1 449 834 (2004-08-01), None
patent: 61214793 (1987-02-01), None
patent: WO 91/00092 (1991-01-01), None
patent: WO 95/03297 (1995-02-01), None
patent: WO 97/32604 (1997-09-01), None
patent: WO 97/36587 (1997-10-01), None
patent: WO 98/52559 (1998-11-01), None
patent: WO 99/20624 (1999-04-01), None
patent: WO 99/32106 (1999-07-01), None
patent: WO 99/32436 (1999-07-01), None
patent: WO 99/32455 (1999-07-01), None
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/42012 (2000-07-01), None
patent: WO 00/71535 (2000-11-01), None
patent: WO 02/04447 (2002-01-01), None
patent: WO 02/062763 (2002-08-01), None
patent: WO 02/083628 (2002-10-01), None
patent: WO 02/085857 (2002-10-01), None
patent: WO 03/000682 (2003-01-01), None
patent: WO 03/033502 (2003-04-01), None
patent: WO 03/047523 (2003-06-01), None
patent: WO 03/047579 (2003-06-01), None
patent: WO 03/068223 (2003-08-01), None
patent: WO 03/068229 (2003-08-01), None
patent: WO 03/068746 (2003-08-01), None
patent: WO 03/087087 (2003-10-01), None
patent: WO 03/102139 (2003-12-01), None
patent: WO 2004/014870 (2004-02-01), None
patent: WO 2004/019941 (2004-03-01), None
patent: WO 2004/037789 (2004-05-01), None
patent: WO 2004/072025 (2004-08-01), None
patent: WO 2004/080464 (2004-09-01), None
patent: WO 2004/085399 (2004-10-01), None
patent: WO 2004/087905 (2004-10-01), None
patent: WO 2004/089929 (2004-10-01), None
patent: WO 2005/023761 (2005-03-01), None
Schreiber, et al., Clin. Gastroenterol. Hepatol., Mar. 2006, 4(3): 325-334 (PubMed abstract).
Sun, et al., Exp. Neurol. Oct. 2003; 183(2): 394-405 (abstract).
Newton, et al., Drug Discovery Today: Disease Mechanisms, 2006, pp. 53-61.
See, et al., Drug Discovery Today: Disease Mechanisms, 2004, pp. 149-154.
Feldmann, Nature Immunology, vol. 2, No. 9, Sep. 2001, pp. 771-773.
Hashimoto, et al., J. of Pharmacol. & Exper. Therap., vol. 293, No. 2, pp. 370-375, 2000.
Johnson, et al., Science, vol. 298, Dec. 6, 2002, 1911-1912.
Yang, et al., J. Leukocyte Biol., 2005;78:1-8.
Dodeller, Arth. Res. & Therapy 2006, 8:205.
Adams et al., “Pyrimidinylimidazole Inhibitors of CSBP/p38 Kinase Demonstrating Decreased Inhibition of Hepatic Cytochrome P450 Enzymes,,”Bioorg. Med. Chem. Lett., 8:3111-3116 (1998).
Adams et al., “Pyrimidinylimidazole Inhibitors of p38: Cyclic N-1 Imidazole Substituents Enhance p38 Kinase Inhibition and Oral Activity,”Bioorg. Med. Chem. Lett., 11:2867-2870 (2001).
Badger et al., “Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function,”J. Pharmacol. Exp. Ther., 279:1453-1461 (1996).
Bingham, “The Pathogenesis of Rheumatoid Arthritis: Pivotal Cytokines Involved in Degradation and Inflammation,”J. Rheumatol. Suppl., 65:3-9 (2002).
Boehm et al., “New Inhibitors of p38 Kinase,”Expert Opinion on Therapeutic Patents, 10(1):25-37 (2000).
Bondeson et al., “Tumour Necrosis Factor as a Therapeutic Target in Rheumatoid Arthritis and Other Chronic Inflammatory Diseases: The Clinical Experience with Infliximab (REMICADE),”Int. J. Clin. Pract., 55:211-216 (2001).
Bradley and Robinson, Kationoid Reactivity of Aromatic Compounds. Part I, (Database Beilstein, Beilstein Institute zur Foerderung der Wissenschaften), Accession No. 316203,J. Chem. Soc. 1254-1263 (1932).
Brinkman et al., “Engagement of Tumor Necrosis Factor (TNF) Receptor 1 Leads to ATF-2- and p38 Mitogen-Activated Protein Kinase-Dependent TNF-alpha Gene Expressidn,”J. Biol. Chem., 274:30882-30886 (1999).
Dong et al., “MAP Kinases in the Immune Response,”Annu. Rev. Immunol., 20:55-72 (2002).
English et al., “Pharmacological Inhibitors of MAPK Pathways,”Trends in Pharmacological Sciences, 23:40-45 (2002).
Enslen et al., “Selective Activation of p38 Mitogen-Activated Protein (MAP) Kinase Isoforms by the MAP Kinase Kinases MKK3 and MKK6,”J. Biol. Chem., 273:1741-1748 (1998).
Feldmann et al., “Role of Cytokines in Rheumatoid Arthritis,”Annu. Rev. Immunol., 14:397-440 (1996).
Fresneda et al., “Synthetic Studies Towards the 2-Aminopyrimidine Alkaloids Variolins and Meridianins from Marine Origin,”Tetrahedron Letters, 41:4777-4780 (2000).
Fuchs et al., “Stability of the ATF2 Transcription Factor is Regulated by Phosphorylation and Dephosphorylation,”J. Biol. Chem., 275:12560-12564 (2000).
Griswold et al., “Differentiation in vivo of Classical Non-Steroidal Antiinflammatory Drugs from Cytokine Suppressive Antiinflammatory Drugs and Other Pharmacological Classes Using Mouse Tumour Necrosis Factor Alpha Production,”Drugs Exp. Clin. Res., 19:243-248 (1993).
International Search Report for International Application No. PCT/US2004/015368.
International Search Report for International Application No. PCT/US2004/024441.
International Search Report for International Application No. PCT/US2004/037390.
Joe et al., “Animal Models of Rheumatoid Arthritis and Related Inflammation,”Curr. Rheumatol. Rep., 1:139-148(1999).
Keesler et al., “Purification and Activation of Recombinant p38 Isoforms Alpha, Beta, Gamma, and Delta,”Protein Expr. Purif., 14:221-228 (1998).
Keffer et al., “Transgenic Mice Expressing Human Tumour Necrosis Factor: A Predictive Genetic Model of Arthritis,”EMBO J., 10:4025-4031 (1991).
Laufer et al., “An in vitro Screening Assay for the Detection of Inhibitors of Proinflammatory Cytokine Synthesis: a Useful Tool for the Development of New Antiarthritic and Disease Modifying Drugs,”Osteoarthritis Cartilage, 10:961-967 (2002).
Laufer and Wagner, “From Imidazoles to Pyrimidines: New Inhibitors of Cytokine Release,”J. Med. Chem., 45:2733-2740 (2002).
Lee et al., “A Protein Kinase Involved in the Regulation of Inflammatory Cytokine Biosynthesis,”Nature, 372:739-746 (1994).
Lee et al., “Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors,”Ann.
Ali Syed
Ashwell Mark A.
Hill Jason
Liu Yanbin
Wrona Woj
Arqule Inc.
Jaisle Cecilia M
Sunstein Kann Murphy & Timbers LLP
Wilson James O
LandOfFree
1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4214127